Author

N. Onishi

Institution: University of California, San Francisco

Observed institution: University of California, San Francisco

OpenAlex ID: A5126210249

Abstract PD6-09: Quantifying the Contribution of Doxorubicin and Cyclophosphamide (AC) to Pathologic Response Following Neoadjuvant Taxane Therapy: Analysis of the I-SPY2 TRIAL

2026 · D. Yee, C. Yau, et al. · Clinical Cancer Research

Abstract PS1-06-11: Fibroblast activation protein (FAP)-targeted dedicated breast PET for primary invasive lobular carcinoma: A pictorial review

2026 · N. Onishi, R. Mukhtar, et al. · Clinical Cancer Research

Abstract PD6-03: Validation of MRI predictive models for treatment optimization in the I-SPY 2 TRIAL

2026 · W. Li, N. Onishi, et al. · Clinical Cancer Research

Abstract PS3-07-22: Correlation between MRI background parenchymal enhancement and serum estradiol in premenopausal patients on neoadjuvant endocrine therapy for breast cancer

2026 · S. Choi, N. Onishi, et al. · Clinical Cancer Research

Works count: 4

Citation count:

H-index:

I10-index: